articles
- Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. 27:976-991. 2020
- Salmonella Typhoid Toxin PltB Subunit and Its Non-typhoidal Salmonella Ortholog Confer Differential Host Adaptation and Virulence. 27:937-946. 2020
- Human Influenza Virus Hemagglutinins Contain Conserved Oligomannose N-Linked Glycans Allowing Potent Neutralization by Lectins. 27:725-735. 2020
- Rational Vaccine Design in the Time of COVID-19. 27:695-698. 2020
- Convergent Evolution in Breadth of Two V(H)6-1-Encoded Influenza Antibody Clonotypes from a Single Donor. 28:434-444. 2020
- Influenza H7N9 virus neuraminidase-specific human monoclonal antibodies inhibit viral egress and protect from lethal influenza infection in mice. 26:715-728. 2019
- Structural basis of protection against H7N9 influenza virus by human anti-N9 neuraminidase antibodies. 26:729-738. 2019
- A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. 26:336-346. 2019
- ARIH2 is a Vif-dependent regulator of CUL5-mediated APOBEC3G degradation in HIV infection. 26:86-99. 2019
- Conformational plasticity in the HIV-1 fusion peptide facilitates recognition by broadly neutralizing antibodies. 25:873-883. 2019
- Preventing an antigenically disruptive mutation in egg-based H3N2 seasonal influenza vaccines by mutational incompatibility. 25:836-844. 2019
- Complement seals a virus to block infection. 25:482-483. 2019
- A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates. 25:49-58. 2019
- Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection. 25:39-48. 2019
- Recurring and adaptable binding motifs in broadly neutralizing antibodies to influenza virus are encoded on the D3-9 segment of the Ig gene. 24:569-578. 2018
- A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus. 24:221-233. 2018
- The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding. 23:101-109. 2018
- A highly pathogenic avian H7N9 influenza virus isolated from a human Is lethal in some ferrets infected via respiratory droplets. 22:615-626. 2017
- Breaking the barrier: host cell invasion by Lujo virus. 22:583-585. 2017
- SMYD2-mediated histone methylation contributes to HIV-1 latency. 21:569-579. 2017
- Breaking down walls: Microbiota and the aging gut. 21:417-418. 2017
- Transcriptional elongation of HSV immediate early genes by the super elongation complex drives lytic infection and reactivation from latency. 21:507-517. 2017
- Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for increased avidity. 21:23-34. 2017
- Diversity of functionally permissive sequences in the receptor-binding site of influenza hemagglutinin. 21:742-753. 2017
- Intracellular action of a secreted peptide required for fungal virulence. 19:849-864. 2016
- Guanylate binding protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. 19:504-514. 2016
- Microbes without borders: decompartmentalization of the aging gut. 19:133-135. 2016
- Meta- and orthogonal integration of influenza "OMICs'' data defines a role for UBR4 in virus budding. 18:723-735. 2015
- Global mapping of the Inc-human interactome reveals that retromer restricts Chlamydia infection. 18:109-121. 2015
- Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. 17:653-661. 2015
- New advances in the effort against Ebola. 17:545-547. 2015
- A human-infecting H10N8 influenza virus retains a strong preference for avian-type receptors. 17:377-384. 2015
- Structure and receptor binding of the hemagglutinin from a human H6N1 influenza virus. 17:369-376. 2015
- Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. 16:412-418. 2014
- The intracellular cargo receptor ERGIC-53 is required for the production of infectious arenavirus, coronavirus, and filovirus particles. 14:522-534. 2013
- Networking at the level of host immunity: immune cell interactions during persistent viral infections. 13:652-664. 2013
- Proteome-wide quantification and characterization of oxidation-sensitive cysteines in pathogenic bacteria. 13:358-370. 2013
- Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. 13:227-237. 2013
- The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. 13:452-464. 2013
- A blueprint for HIV vaccine discovery. 12:396-407. 2012
- Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. 12:558-570. 2012
- An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. 12:97-108. 2012
- An all-purpose antimalarial drug target. 11:555-557. 2012
- Selective and specific inhibition of the plasmodium falciparum lysyl-trna synthetase by the fungal secondary metabolite cladosporin. 11:654-663. 2012
- Toll-like receptor 7 is required for effective adaptive immune responses that prevent persistent virus infection. 11:643-653. 2012
- Pancreatic acinar cell-specific autophagy disruption reduces coxsackievirus replication and pathogenesis in vivo. 11:298-305. 2012
- Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. 11:205-217. 2012
- Hypomorphic mutation in the site-1 protease Mbtps1 endows resistance to persistent viral infection in a cell-specific manner. 9:212-222. 2011
- Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. 6:513-522. 2009
- Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. 5:439-449. 2009
- Persistent virus infection inhibits type i interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. 4:374-386. 2008
- Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. 4:239-248. 2008
- Liver autoimmunity triggered by microbial activation of natural killer T cells. 3:304-315. 2008
- Mechanism of adenovirus neutralization by human alpha-defensins. 3:11-19. 2008